



**Innovative back microsurgery**

**Press Release**

**VEXIM Strengthens its Management Team, with the Appointment of Sandrine Carle as Marketing Director.**

Toulouse, France - February 18, 2014 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced today the appointment of Sandrine Carle as Marketing Director. In her new role, Sandrine will contribute to VEXIM's growth by extending its business into new international markets.

Before joining VEXIM, Sandrine held a series of operational and strategic roles at Medtronic over a 15-year period and particularly developed strong skills in the spine field. Along with her in-depth knowledge of global markets, her resolutely international skills and profile are true assets that will further underpin VEXIM's strong ongoing growth.

Sandrine Carle (43 years of age) graduated with a Master's in Biomedical Engineering from Compiègne University of Technology (France) in 1994. She also obtained an Executive MBA from HEC Paris in 2013. Her career started in Regulatory Affairs at Aesculap France, where she gained her first experience of international markets (1995-1996). Sandrine joined Medtronic soon after - first in France and then abroad, supervising neuromodulation clinical trials for the entire E.M.E.A market. In 2006, she joined Medtronic's Europe, Middle East and Africa marketing team for spine products and then (from 2009 onwards) led the group's global marketing for treatments of lumbar stenosis and vertebral fractures. This involved a move to Sunnyvale (CA), where she also gained experience of the North American domestic market. In 2011, Sandrine collaborated with the International Osteoporosis Foundation to develop new fundraising strategies. After obtaining her Executive MBA in June 2013, she served as Head of Global Marketing at Leica Microsystems's Ophthalmology Department in Heerbrugg, Switzerland.

*"We are delighted to welcome Sandrine to the company. Her experience and skills will add to VEXIM's assets. This appointment confirms our commitment to building a major, sustainable growth-focused company with significant added value for our shareholders. Her thorough knowledge of spine markets, her international profile and successful experience in many types of market will allow us to extend our current European presence to the global stage", commented VEXIM CEO Vincent Gardès.*

## 2014 preliminary financial agenda\*:

FY 2013 results: March 18, 2014

H1 2014 sales: July 22, 2014

\*Indicative dates, subject to potential modifications

### About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital<sup>1</sup> and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 50 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3<sup>rd</sup> 2012. For further information, please go to [www.vexim.com](http://www.vexim.com)

### SpineJack®<sup>2</sup>, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

### Contacts

#### VEXIM

**Vincent Gardès**

CEO

Tel: +33 5 61 48 48 38

[shareholders@vexim.com](mailto:shareholders@vexim.com)

#### NewCap.

Financial Communications  
and Investor Relations

**Dusan Oresansky /**

**Emmanuel Huynh**

Tel: +33 1 44 71 94 92

[vexim@newcap.fr](mailto:vexim@newcap.fr)

#### Alize RP

Press Relations

**Caroline Carmagnol**

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Tel: +33 6 64 18 99 59



- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

<sup>1</sup> Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit [www.truffle.fr](http://www.truffle.fr) and [www.fcpi.fr](http://www.fcpi.fr).

<sup>2</sup> This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.